Consensus Valerio Therapeutics Deutsche Boerse AG

Equities

C4X

FR0010095596

Delayed Deutsche Boerse AG Other stock markets 08:17:49 05/07/2024 BST			5-day change	1st Jan Change
0.09 ^EUR	-13.46%		-10.00%	-40.59%

05-22	Valerio Therapeutics S.A. Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial	CI
04-30	Valerio Therapeutics Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Evolution of the average Target Price on Valerio Therapeutics

Price target over the last 5 years

History of analyst recommendation changes

56956db4af17b6f75f70b.NHU4v23M1I8SgusV01sfi4EoUmk3NSYnwfKoE_OWhUo.XxlZ9R2J-ctW-95j5BpL1ORDHzliYnRJq5_NJLGv7jxiWGH1FPyi4WjM0w~573b5ff36f6a211e13d9702ed12b62ad

Analyst Recommendations on Valerio Therapeutics

Onxeo : Bryan Garnier & Co initiates the coverage of Onxeo with a “Buy” recommendation	29/05/20	PU
Bryan Garnier & Co Initiates Coverage of Onxeo with a “Buy” Recommendation	27/05/20	GL
Onxeo : Bryan Garnier & Co Initiates the Coverage of Onxeo with a “Buy” Recommendation	27/05/20	BU

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.105 EUR

Average target price

1.2 EUR

Spread / Average Target

+1,042.86%

High Price Target

1.2 EUR

Spread / Highest target

+1,042.86%

Low Price Target

1.2 EUR

Spread / Lowest Target

+1,042.86%

Consensus detail

Consensus revision (last 18 months)

Annual profits - Rate of surprise

Company calendar